Form 4: Research Frontiers Inc. CEO Acquires Stock Options

Sentiment:

SEC Form 4 Filing


Research Frontiers Inc.'s CEO, Joseph M. Harary, was granted 60,000 stock options, with a portion contingent on shareholder approval.

Summary

  • Joseph M. Harary, the President and CEO of Research Frontiers Inc., was granted 60,000 stock options on December 31, 2024.
  • The options have an exercise price of $1.68 per share.
  • 37,265 of these options are contingent on shareholder approval at the 2025 Annual Meeting of Stockholders for additional shares under the 2019 Equity Incentive Plan.
  • If shareholder approval is not obtained, these contingent options will automatically terminate.
  • The options expire on December 30, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. The contingency on shareholder approval adds a layer of corporate governance.

Positives

  • The grant of stock options to the CEO aligns his interests with those of the shareholders.
  • The vesting of a portion of the options is contingent on shareholder approval, which could encourage management to act in the best interests of the shareholders.

Risks

  • The contingent options will terminate if shareholder approval is not received at the 2025 Annual Meeting, which could impact the CEO's compensation.

Future Outlook

The grant of stock options is part of the company's long-term incentive plan, with a portion contingent on shareholder approval at the 2025 Annual Meeting.

Industry Context

Stock option grants are a common form of executive compensation in publicly traded companies, aligning management's interests with those of shareholders.

Comparison to Industry Standards

  • Stock option grants are a standard practice for executive compensation across various industries.
  • The specific terms of the grant, such as the exercise price and vesting conditions, are typical for such arrangements.
  • The contingency on shareholder approval is a measure to ensure alignment with shareholder interests, which is a common practice.

Stakeholder Impact

  • Shareholders will be asked to approve additional shares for the 2019 Equity Incentive Plan, which is required for the vesting of a portion of the CEO's stock options.
  • The CEO's compensation is impacted by the grant of stock options.

Next Steps

  • Shareholder approval will be sought at the 2025 Annual Meeting for the contingent portion of the stock options.

Key Dates

DateDescription
12/31/2024Date of the stock option grant.
12/30/2034Expiration date of the stock options.
01/02/2025Date the form was signed.

Keywords

stock options, equity incentive plan, shareholder approval, executive compensation, Research Frontiers Inc, Joseph M. Harary

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.